Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Inc (NQ: VCYT ) 23.57 +0.54 (+2.34%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Veracyte Inc < Previous 1 2 3 4 5 6 Next > Veracyte to Participate in Upcoming Investor Conferences February 27, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results February 22, 2023 From Veracyte, Inc. Via Business Wire Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer February 15, 2023 From Veracyte, Inc. Via Business Wire New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment February 13, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023 February 06, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium February 01, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules February 01, 2023 From Veracyte, Inc. Via Business Wire Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors January 23, 2023 From Exagen Inc. Via GlobeNewswire Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis December 15, 2022 From Veracyte, Inc. Via Business Wire Veracyte Announces Third Quarter 2022 Financial Results November 02, 2022 From Veracyte, Inc. Via Business Wire Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting November 01, 2022 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference October 27, 2022 From Veracyte, Inc. Via Business Wire New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy October 25, 2022 From Veracyte, Inc. Via Business Wire Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer October 24, 2022 From Veracyte, Inc. Via Business Wire New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer October 18, 2022 From Veracyte, Inc. Via Business Wire Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022 October 13, 2022 From Veracyte, Inc. Via Business Wire New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men September 22, 2022 From Veracyte, Inc. Via Business Wire Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access September 13, 2022 From Veracyte, Inc. Via Business Wire New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer September 11, 2022 From Veracyte, Inc. Via Business Wire New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy September 07, 2022 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference September 01, 2022 From Veracyte, Inc. Via Business Wire Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022 August 31, 2022 From Veracyte, Inc. Via Business Wire New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma August 29, 2022 From Veracyte, Inc. Via Business Wire Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors August 11, 2022 From Veracyte, Inc. Via Business Wire Veracyte Announces Second Quarter 2022 Financial Results August 02, 2022 From Veracyte, Inc. Via Business Wire Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid July 20, 2022 From Veracyte, Inc. Via Business Wire Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022 July 14, 2022 From Veracyte, Inc. Via Business Wire New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis July 13, 2022 From Veracyte, Inc. Via Business Wire Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year June 27, 2022 From Veracyte, Inc. Via Business Wire New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice June 20, 2022 From Veracyte, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.